Search

Displaying results 2411 - 2420 of 4004 in total
  1. Drug

    Hyaluronidase (ovine)

    go.drugbank.com/drugs/DB00070
    Approved

    Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.

  2. Drug

    Proparacaine

    go.drugbank.com/drugs/DB00807
    ApprovedVet approved

    Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

  3. Drug

    Tragacanth

    go.drugbank.com/drugs/DB10667
    Approved

    Tragacanth allergenic extract is used in allergenic testing.

    Categories: Non-Standardized Food Allergenic Extract, Non-Standardized Plant Allergenic Extract
  4. Drug

    Ethotoin

    go.drugbank.com/drugs/DB00754
    Approved

    Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter d...

  5. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety ...

  6. Drug

    Anti-SARS-CoV-2 REGN-COV2

    go.drugbank.com/drugs/DB15691
    Investigational

    [L14306] Clinical trials for this drug started on June 11, 2020. … Regeneron's clinical trial will study the effects of this drug on hospitalized COVID-19 patients, symptomatic COVID-19 patients (non-hospitalized), and uninfected individuals at high-risk of infection,

  7. Drug

    Dexepicatechin

    go.drugbank.com/drugs/DB19253
    Investigational

    Dexepicatechin is under investigation in clinical trial NCT02964377 (Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents).

  8. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … [L64068,L64069] Unlike existing narcolepsy treatments such as stimulants and sedatives, which manage individual symptoms, oveporexton acts on the underlying orexin deficiency that drives the disorder.

  9. Drug

    ETX101

    go.drugbank.com/drugs/DB18579
    Investigational

    ETX101 is a non-replicating recombinant adeno associated viral vector, serotype 9, designed to promote increased transcription of SCN1A gene.

    Synonyms: non-replicating recombinant adeno associated viral vector, serotype 9, designed to promote increased transcription of SCN1A gene
  10. Drug

    PBFT02

    go.drugbank.com/drugs/DB18580
    Investigational

    PBFT02 is a non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin.

    Synonyms: Non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin